Clinician’s Guide to Prevention and Treatment of Osteoporosis
Open accessThe DOI matches its Crossref record; 101 of the 102 references it cites were found in a registry or an index; 41 of the 169 sources its claims cite were checked for support.
Abstract
The Clinician's Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with a multispecialty council of medical experts in the field of bone health convened by NOF. Readers are urged to consult current prescribing information on any drug, device, or procedure discussed in this publication.
Overview
CoChat Summary
TL;DR
This NOF Clinician’s Guide provides recommendations for prevention, risk assessment, diagnosis, and treatment of osteoporosis in postmenopausal women and men age 50 and older, including BMD testing, vertebral imaging, FRAX-based intervention thresholds, and FDA-approved pharmacotherapy. It emphasizes that osteoporosis is common, underdiagnosed, and treatable, with treatment thresholds and drug-specific fracture risk reductions summarized.
Key findings
- Osteoporosis affects more than 9.9 million Americans, with an additional 43.1 million having low bone density; about 1 in 2 Caucasian women and approximately 1 in 5 men will experience an osteoporosis-related fracture. Annually, 2 million fractures are attributed to osteoporosis, causing more than 432,000 hospital admissions, almost 2.5 million medical office visits, and about 180,000 nursing home admissions; costs are expected to rise to $25.3 billion by 2025. Only 23% of women age 67 or older who have an osteoporosis-related fracture receive either a BMD test or a prescription for osteoporosis drug in the 6 months after fracture.
- Pharmacologic treatment is recommended for hip or vertebral fracture, T-score ≤−2.5 at the femoral neck, total hip, or lumbar spine, or low bone mass (T-score between −1.0 and −2.5) with a 10-year hip fracture probability ≥3% or a 10-year major osteoporosis-related fracture probability ≥20% by US-adapted FRAX.
- Universal recommendations include calcium intake of 1000 mg/day for men 50–70 and 1200 mg/day for women 51 and older and men 71 and older; vitamin D 800–1000 IU/day for adults age 50 and older; regular weight-bearing and muscle-strengthening exercise; fall risk assessment and modification; smoking cessation; and avoidance of excessive alcohol.
- Selected drug efficacy data: alendronate reduces spine and hip fractures by about 50% over 3 years; zoledronic acid reduces vertebral fractures by 70%, hip fractures by 41%, and nonvertebral fractures by 25% over 3 years; denosumab reduces vertebral fractures by about 68%, hip fractures by about 40%, and nonvertebral fractures by about 20% over 3 years; teriparatide reduces vertebral fractures by about 65% and nonvertebral fragility fractures by about 53%; raloxifene reduces vertebral fractures by about 30% with prior vertebral fracture and about 55% without; calcitonin reduces vertebral fracture occurrence by about 30% but has not been shown to reduce nonvertebral fractures; ibandronate reduces vertebral fractures by about 50% but nonvertebral fracture reduction has not been documented.
Methods
- Design: guideline developed by an expert committee of the National Osteoporosis Foundation in collaboration with a multispecialty council of medical experts in bone health; recommendations apply to postmenopausal women and men age 50 and older.
- Data or sample: no primary study sample; the Guide synthesizes evidence including NHANES III prevalence estimates, the Women’s Health Initiative, FDA prescribing information, WHO FRAX, and cost-effectiveness analyses.
- Main analysis: expert consensus and evidence synthesis; absolute risk thresholds for pharmacologic intervention were guided by a cost-effectiveness analysis; diagnostic assessment uses central DXA, vertebral imaging, and US-adapted WHO FRAX.
Limitations
- Stated: FRAX underestimates fracture risk in patients with recent fractures, multiple osteoporosis-related fractures, and increased fall risk; it has not been validated for lumbar spine BMD, is not intended for younger adults or children, and has not been validated in patients currently or previously treated with osteoporosis pharmacotherapy.
- Stated: evidence of efficacy beyond 5 years is limited; rare safety concerns such as osteonecrosis of the jaw and atypical femur fractures become more common beyond 5 years; there are relatively few data confirming fracture risk reductions with pharmacotherapy in patients selected by low bone mass plus FRAX thresholds; fracture data are limited in glucocorticoid-induced osteoporosis and in men; and in the absence of head-to-head trials, direct comparisons of risk reduction among drugs should be avoided.
- Evident: the text does not report a systematic search strategy or formal evidence-grading system; the therapeutic thresholds are described as clinical guidance only and “not rules,” requiring individualized clinical judgment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Micrographs of normal vs. osteoporotic bone [9], from Dempster et al., with permission of The American Society for Bone and Mineral Research [9]](https://figures.cochat.ai/paper-figures/d609b75c87444980afa9b5aebc701061/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-1.jpg)
![Fig. 2 Pathogenesis of osteoporosis-related fractures, from Cooper and Melton, with modification [10]](https://figures.cochat.ai/paper-figures/ff3ff2f3f4b84a5bbd00a8cc79080d62/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-2.jpg)

Verification
Claims the paper makes
29 Valid · 18 Not valid · 68 Not checked · 17 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Raloxifene is also indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [83–86].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Estrogen agonist/antagonist (formerly known as SERMs): Raloxifene
What the sources say
- Not checked — no full text of the sourcecites [83] Cauley JA Norton L Lippman ME Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation Breast Cancer Res Treat 2001 65 2 125 134 10.1023/A:1006478317173 11261828 source
- Disputedcites [84] Martino S Cauley JA Barrett-Connor E CORE Investigators Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 2004 96 23 1751 1761 10.1093/jnci/djh319 15572757 sourceExperimental — accuracy not yet measured
The introduction (p. 1) says raloxifene was approved for preventing and treating postmenopausal osteoporosis, while tamoxifen was the only agent approved in the United States to reduce breast cancer incidence. Although the CORE results (p. 5) show reduced invasive breast cancer incidence with raloxifene, they do not support the claim that breast cancer risk reduction was an approved indication. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [85] Vogel VG Costantino JP Wickerham DL National Surgical Adjuvent Breast and Bowel Project (NSABP) Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 2006 295 23 2727 2741 10.1001/jama.295.23.joc60074 16754727 source
- Partly supportedcites [86] Barrett-Connor E Mosca L Collins P Raloxifene Use for The Heart (RUTH) Trial Investigators Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 2006 355 2 125 137 10.1056/NEJMoa062462 16837676 sourceExperimental — accuracy not yet measured
The Primary Outcomes (p. 5) report that raloxifene reduced invasive breast cancer in the RUTH trial, and the introductory text (p. 2) reports a similar finding from MORE, an osteoporosis-treatment trial. The paper does not state that breast-cancer risk reduction is an approved indication for postmenopausal women with osteoporosis; RUTH enrolled women with or at increased risk for coronary heart disease. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Bisphosphonates
What the sources say
- Disputedcites [50] Chesnut CH 3rd Skag A Christiansen C Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 2004 19 18 1241 1249 10.1359/JBMR.040325 15231010 sourceExperimental — accuracy not yet measured
The Clinical osteoporotic nonvertebral fractures section reports a statistically significant 69% reduction with daily ibandronate in women with a baseline femoral-neck BMD T score below −3.0. The Discussion cautions that this was a post hoc analysis and says there was no significant reduction in the overall population, but the unqualified claim that a reduction has not been documented overlooks the reported subgroup finding. Page numbers were not provided in the supplied passages. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A vertebral fracture is consistent with a diagnosis of osteoporosis, even in the absence of a bone density diagnosis, and is an indication for pharmacologic treatment with osteoporosis medication to reduce subsequent fracture risk [18, 21].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Vertebral imaging
What the sources say
- Not checked — no full text of the sourcecites [18] Kanis JA Melton LJ 3rd Christiansen C Johnston CC Khaltaev N The diagnosis of osteoporosis J Bone Miner Res 1994 9 8 1137 1141 10.1002/jbmr.5650090802 7976495 source
- Supportedcites [21] Melton LJ Chrischilles EA Cooper C Lane AW Riggs BL How many women have osteoporosis? J Bone Miner Res 2005 20 5 886 892 10.1359/jbmr.2005.20.5.886 15931736 source
The conclusion (OSTEOPENIA, p. 6) distinguishes osteoporosis assessed by bone mineral measurements from established osteoporosis assessed by the occurrence of specific fractures. The introduction (p. 2) identifies vertebral fractures among the principal osteoporosis-related fractures, supporting the stated diagnosis without a bone-density diagnosis. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Help determine adequacy of patient compliance and persistence with osteoporosis therapy”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The review’s “Compliance and persistence” section describes a model in which a bone turnover marker result could lead to a conclusion that compliance or treatment response was inadequate, but notes that the model did not include test-accuracy data. “Measures of adherence” says that a marker-identified non-response could reflect non-compliance or non-persistence, among several other causes. The source therefore supports markers as a possible clue, not as a way to determine the adequacy of both compliance and persistence. (LLM, conf=0.83)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Predict magnitude of BMD increases with FDA-approved therapies”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The Clinical Effectiveness and Cost-Effectiveness Evidence section reports correlations between changes in bone turnover markers and BMD, including a statistically significant but weak correlation during teriparatide treatment. It also says not all correlations were significant and cautions that their usefulness varies by population. The review does not establish that markers predict the magnitude of BMD increases across FDA-approved therapies generally. (LLM, conf=0.84)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
87 more claims · 25 with their cited sources checked
Create a free account to see all 132 claims and to verify the 18 references still open.
- Probably not a substantial claim. 26
- It may state two separate claims as one. 25
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“this equated to a health care cost of $1088”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previous studies31,46,47,48 in emergency department patients have identified primarily benefits, including reductions in health care costs, medical retirement, and depressive symptoms.”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredIn the citing paper
“yielding an uptake of 89.9%”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
In the citing paper
“this issue was addressed by instead performing a thorough cost accounting from 2 specific exemplar interventions.30,31”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Diagnostic assessment
“Screening BMD and vertebral imaging recommendations for men are outlined in Table 8.”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Additional bone densitometry technologies
“Table: Table 8 Additional bone densitometry technologies”
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025
Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., & Tosteson, A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061113 · Cited by 4,026
Interventions for preventing falls in older people living in the community
Gillespie, L. D., Robertson, M. C., Gillespie, W. J., Sherrington, C., Gates, S., Clemson, L., & Lamb, S. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007146.pub3 · Cited by 3,966
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489 · cited 1×
“by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
BackgroundDecreased bioavailability of vitamin D in obesity
Wortsman, J., Matsuoka, L. Y., Chen, T. C., Lu, Z., & Holick, M. F. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/72.3.690 · Cited by 3,204 · cited 1×
“This regimen should be followed by maintenance therapy of 1500–2000 IU/day or whatever dose is needed to maintain the target blood level [37, 38].”
Background
Research works printed but not linked: 4
- Office of the Surgeon General (US) (2004) Bone health and osteoporosis: a report of the Surgeon General. Office of the Surgeon General (US), Rockville (MD). Available from: http://www.ncbi.nlm.nih.gov/books/NBK45513/. Accessed March 2014 20945569
- National Osteoporosis Foundation Physician’s guide to prevention and treatment of osteoporosis 2005 Washington, DC National Osteoporosis Foundation
- Institute of Medicine (US) Committee to review dietary reference intakes for vitamin D and calcium (2011). In: Ross AC, Taylor CL, Yaktine AL et al (eds) Dietary reference intakes for calcium and vitamin D. National Academies Press (US), Washington (DC). Available from: http://www.ncbi.nlm.nih.gov/books/NBK56070/. Accessed March 2014 21796828
- Cummings, SR, San Martin J, McClung MR et al (2009) FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765. (Erratum in: N Engl J Med. 2009;36(10):191) 19671655 · DOI · Paper page
Cited by
Items 3,301–3,400 of 4,108
ASUPAN PROTEIN YANG KURANG SEBAGAI FAKTOR RISIKO KEPADATAN TULANG RENDAH PADA WANITA PASCAMENOPAUSE
Pradipta, D. R., & Dieny, F. F. (2014) · Journal of Nutrition College · doi:10.14710/jnc.v3i4.6861
The Diagnosis and Workup of Patients for Osteoporosis or Osteopenia (Low Bone Mass)
Bonura, F. (2012) · InTech eBooks · doi:10.5772/31697
Theiler, R., & Kränzlin, M. (2014) · Gynäkologische Endokrinologie · doi:10.1007/s10304-014-0642-2
Use of osteoporosis medications among Turkish patients
Aypak, C., Türedi, Ö., Bircan, M. A., et al. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.381
The cardio-metabolic profile and bone mineral density in African and Indian postmenopausal women.
Moodley, J. (2013) · ResearchSpace (University of KwaZulu-Natal)
Mughal, D. T. (2018) · Springer eBooks · doi:10.1007/978-3-319-90083-4_13
Functional Anatomy and Imaging of the Spine
Keel, J. C., & Brenner, G. J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-1560-2_22
Hip Fracture: Managing the Medically Complex, Older Surgical Patient
Grant, P. (2013) · Wiley eBooks · doi:10.1002/9781118674963.ch9
Fronza, F. C. A. O. (2012) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.39.2012.tde-28052012-155126
Approach to the Screening and Diagnosis of Osteoporosis
Choi, H. J. (2012) · InTech eBooks · doi:10.5772/31125
Chapter 55. Cost‐Effectiveness of Osteoporosis Treatment
Tosteson, A. N. A. (2008) · Wiley eBooks · doi:10.1002/9780470623992.ch55
Alexander, I. M. (2011) · Wiley eBooks · doi:10.1002/9781118785607.ch18
Clinical and Research Applications of Bone Mineral Density Examinations
Lenchik, L., Wuertzer, S. D., & Register, T. C. (2014) · Springer eBooks · doi:10.1007/978-1-4939-2001-3_6
Elnefily, R. (2013) · uO Research (University of Ottawa) · doi:10.20381/ruor-3060 · Cited by 2
İlhan, B., Tufan, F., Gulistan, B., & Karan, M. A. (2015) · Clinical Interventions in Aging · doi:10.2147/cia.s93068
Pharmacologic Treatment Strategies
Evans, R. A., Varadi, R. G., Mirzaei, K., & Goldstein, R. S. (2011) · Humana Press eBooks · doi:10.1007/978-1-60761-673-3_13
Atitude do consumidor em relação ao leite e produtos derivados na cidade de Maringá – Paraná
Molina, G., Pelissari, F. M., & Feirhmann, A. C. (2013) · Arquivos do Museu Dinâmico Interdisciplinar · doi:10.4025/arqmudi.v13i1/2/3.20015
Using Absolute Risk to Predict Fracture Risk in Clinical Practice
Bonnick, S. L., & Lewis, L. A. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3625-6_8
Denosumab, a RANKL Inhibitor, Induced Osteonecrosis of the Jaw
胡, 龙. (2013) · Hans Journal of Surgery · doi:10.12677/hjs.2013.31001
Valles-Figueroa, J. F., Rodríguez-Reséndiz, F., Muñoz-Arreola, F. J., et al. (2015) · Acta Ortopédica Mexicana
Therapeutical Approach of Osteoporosis — a Multidisciplinary Issue
Camelia, G., Simona, M., & Gliga, M. L. (2013) · Acta Marisiensis. Seria Medica · doi:10.2478/amma-2013-0053
Silva, M., Romeiser, A., Baker, D. W., Didwania, A. K., Brown, T., Feinglass, J. M., Lee, J. Y., & Dolan, N. C. (2013) · Open Journal of Preventive Medicine · doi:10.4236/ojpm.2013.39076
Clinical preventive service and scientific evidence
Park, B. (2011) · Journal of Korean Medical Association · doi:10.5124/jkma.2011.54.3.244
Stuenkel, C. A., & Ettinger, B. B. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00065-0
Osteoporosis in men: who should we treat?
Compston, J. E. (2014) · BMJ · doi:10.1136/bmj.g4229
Dueck, A. C., Singh, J. A., Atherton, P., Liu, H., Novotny, P. J., Hines, S. L., Loprinzi, C. L., Perez, E. A., Tan, A., Burger, K. N., et al. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3091-4
Hollingsworth, T. (2014) · Journal of patient-centered research and reviews · doi:10.17294/2330-0698.1041
Rational decision making; the role of physician
Lekamwasam, S. (2014) · Journal of the Ceylon College of Physicians · doi:10.4038/jccp.v43i1-2.6777
VFA Imaging, Femoral Morphometry, and Hip Structural Analysis
Bonnick, S. L., & Lewis, L. A. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3625-6_13
The safety and efficacy of osteoporosis therapy
Mkele, G. (2015) · Pharmacy management
Interpretation of Bone Densitometry Data
Bonnick, S. L., & Lewis, L. A. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3625-6_10
The Declining Use of Bone Densitometry
Hamdy, R. C. (2015) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2015.04.001
Writers, A. M. (2013) · Drugs & Therapy Perspectives · doi:10.1007/s40267-013-0042-z
Salud ósea en pacientes con cáncer de próstata
López, B. M., Cozar, J. M., Alcaraz, A., Moróte, J., Gómez-Veiga, F., Solsona, E., Rodríguez-Antolín, A., & Carballido, J. (2014) · Actas Urológicas Españolas · doi:10.1016/j.acuro.2014.05.003 · Cited by 1
Commentary: Measuring Quality of Care in Osteoporosis
Silverman, S. L., & Curtis, J. R. (2013) · Current Osteoporosis Reports · doi:10.1007/s11914-013-0176-x
Cesar, R. (2014) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.18.2014.tde-09022015-113119
Quels sont les facteurs de risque et la prise en charge d’une fracture sous bisphosphonate?
Flamand-Villeneuve, J. (2015) · Pharmactuel
Contemporary Recommendations for Primary Care Management of Patients with HIV Infection
Hannah, W. N., & Okulicz, J. F. (2014) · Journal of AIDS & Clinical Research · doi:10.4172/2155-6113.1000e113 · Cited by 1
Medical Assistance Division Medicaid Drug Utilization Review Newsletter
Apfeldorf, W. J., & Bachyrycz, A. M. (2013)
Askin, D. (2015) · Lenus, The Irish Health Repository (Dr Steevens Hospital Library)
Preventing and treating osteoporosis in men
O’Connell, M. B., & Vondracek, S. F. (2013) · Pharmacy Today · doi:10.1016/s1042-0991(15)31276-7
What Are the Perspectives of Osteoporosis Screening Among Black Women
Wilkins, A. A. (2016) · ScholarWorks (Walden University)
Bone Mineral Densitometry: Measurement and Evaluation Methods
Emer, M. Ö., İnce, S., & Arslan, N. (2015) · Springer eBooks · doi:10.1007/978-3-319-20777-3_12
Gonçalves, A. S. D. S., Rodrigues, A. M., Canhão, H. M., & Fonseca, J. E. (2013)
The Effects of Diabetes and Obesity on the Skeleton
Furst, J. R., Bilezikian, J. P., & Rubin, M. R. (2015) · Springer eBooks · doi:10.1007/978-3-319-22431-2_22
Tandheelkundige gevolgen van twee vormen van osteomalacie
van Riet, T. C. T. (2015) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-368-0889-7_13
Bone Health Promotion for Youth: A Primary Care Intervention
Wilson, K. G. (2016)
Sanchez, T. A. (2014) · Language arts journal of Michigan
Diagnóstico de la osteoporosis
Henríquez, M. S., DIa, B., Día, M., et al. (2016)
Bio-Identical Hormones Utilized for Treating Menopausal Symptoms: Are They Safe?
White, M. D. (2015) · San José State University ScholarWorks (San Jose State University) · doi:10.31979/etd.e2ht-8zmu · Cited by 1
The Impact of Regulatory and Scientific Organizations’ Recommendations on Clinical Decision-Making
Παπαϊωάννου, Α., Agarwal, A., & Karampatos, S. (2015) · Springer eBooks · doi:10.1007/978-3-319-23639-1_21
Funayama, B., Freire, A., Corrente, J. E., et al. (2016)
Controversias en el tratamiento de la osteoporosis posmenopáusica
Sotelo, W., & Vásquez, E. A. (2016) · Revista Peruana de Ginecología y Obstetricia · doi:10.31403/rpgo.v62i1910 · Cited by 6
Kuttner, C. (2015) · Springer eBooks · doi:10.1007/978-3-319-16979-8_10
Evidence of dietary calcium and vitamin D inadequacies in a population of dental patients.
Pehowich, D., & Pehowich, E. (2016) · Journal of Evidence-Based Dental Practice · doi:10.1016/j.jebdp.2016.07.005
Bioactive nanomaterials for cartilage and muscle regeneration
Holban, A. M., Andronescu, E., Curuțiu, C., Diţu, L.-M., Chifiriuc, M. C., & Lazăr, V. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-42865-1.00010-6 · Cited by 1
Nock, N. L. (2016) · Wageningen Academic Publishers eBooks · doi:10.3920/978-90-8686-823-0_16
Nontraumatic Vertebral Collapse
Abello, A. L. (2016) · Springer eBooks · doi:10.1007/978-3-319-27987-9_44
17. Supplemental calcium use and vascular outcomes
Rojas‐Fernandez, C. H. (2016) · Wageningen Academic Publishers eBooks · doi:10.3920/978-90-8686-823-0_17
LeBoff, M. S., Yue, A. Y., Cook, N. R., Buring, J. E., & Manson, J. E. (2016) · Springer eBooks · doi:10.1007/978-3-319-32417-3_21
Self-citationPrimary Hyperparathyroidism and Osteoporosis
Ospina, N. S., & Hurley, D. L. (2016) · Springer eBooks · doi:10.1007/978-3-319-25880-5_4
Fostering Resilience Among Older Adults Living with Osteoporosis and Osteoarthritis
Smith, B. J., & Bailey, W. A. (2016) · Emerging issues in family and individual resilience · doi:10.1007/978-3-319-26033-4_9
Bonnick, S. L. (2011) · Elsevier eBooks · doi:10.1016/b978-0-323-06551-1.00042-7
Pointing the Finger at Bone Density Screening: Part II
Falkenberg, A., & Decamps, J. V. (2015) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2015.05.036
Mosua, S. J., & Khairi, S. (2016) · IOSR Journal of Nursing and health Science · doi:10.9790/1959-0504056873
Torner, G., & Queralt, M. A. V. (2016) · TDX (Tesis Doctorals en Xarxa) · Cited by 1
Adecuación de las densitometrías en un centro de atención primaria
Gómez-García, J. M., Romero, F. J. G., Arencibia-Jiménez, M., et al. (2016) · Revista Clínica Española · doi:10.1016/j.rce.2016.07.002
Kates, S. L., & Lipof, J. S. (2016) · Springer eBooks · doi:10.1007/978-3-319-31831-8_15
Can We Determine Who is at Risk of Inpatient Hip Fractures?
Joyce, M., Murphy, C. G., Hurson, C. J., & Clifford, G. (2016) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2016.08.031
The Structure and Prevalence of Major Risk Factors of Osteoporosis in Uzbek Women over 50
Ismailov, S. I., Abboskhujaeva, L. S., Alikhanova, N. M., et al. (2016) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2016.710077
Gladd, D. A. (2015)
Gnerre, P., & Nardi, R. (2016) · Italian Journal of Medicine · doi:10.4081/itjm.q.2016.4
Evaluation of Osteoporosis in Elderly with Novel Diagnostic Tools
MD (Medicine), A. P. I. M., & Bansode, D. M. (2016) · Journal of Medical Science And clinical Research · doi:10.18535/jmscr/v4i12.58
Reumatología. Texto de autoaprendizaje
Giraldo, H. J. U., & Burgos, C. D. A. (2016) · Universidad Tecnológica de Pereira eBooks · doi:10.22517/9789587222630
Başaran, S., Benlidayı, İ. C., Güzel, R., et al. (2015) · Turkish Journal of Osteoporosis · doi:10.4274/tod.87699
Management of Risks Factors for Older Women: Osteoporosis and Cardiovascular Disease
Wade, K. S., & Quaas, A. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-17002-2_47-1
Surveillance of Treated Thyroid Cancer Patients and Thyroid Hormone Replacement and Suppression
Perkins, J. M. (2017) · Springer eBooks · doi:10.1007/978-3-319-43618-0_22
A Case of Atraumatic Fracture Resulting from Physical Restraint in an Elderly Woman
Lim, S. C., & Chow, P. C.-L. (2017) · Journal of Gerontology & Geriatric Research · doi:10.4172/2167-7182.1000387
(2015) · The American Pharmacists Association eBooks · doi:10.21019/9781582122175.ch19
Response to Letter to the Editor of JBMR: Treatment Sequence Matters
Cosman, F., Nieves, J. W., & Dempster, D. W. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3126
Self-citationThe Efficacy of Alendronate Treatment in Ambulatory Stroke Patients
Özaras, N., Demir, S. E., & Arslan, A. (2016) · Bezmialem Science · doi:10.14235/bs.2015.455
Zhang, Y., Xiao, H., & Sheng, Z. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00418
Oleson, C. V. (2017) · Springer eBooks · doi:10.1007/978-3-319-45084-1_6
Interventions and Management of Complications of Osteoporosis
Oleson, C. V., & Morina, A. B. (2017) · Springer eBooks · doi:10.1007/978-3-319-45084-1_5
Correa‐Rodríguez, M., Schmidt‐RioValle, J., & Rueda‐Medina, B. (2017) · Rheumatology International · doi:10.1007/s00296-017-3748-8
on behalf of the PAADRN Investigators, Wolinsky, F. D., Hall, S. F., Lou, Y., Edmonds, S. W., Saag, K. G., Roblin, D. W., Wright, N. C., Jones, M., Cram, P. M., et al. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4113-1
17: Diet and Exercise Approaches for Reversal of Exercise-Associated Menstrual Dysfunction
Cialdella-Kam, L. A., & Manore, M. M. (2017) · CRC Press eBooks · doi:10.1201/9781351260008-17 · Cited by 1
Improving the Pharmacologic Management of Patients after Osteoporotic Hip Fractures
Klaus, J., Modarresi, M., Aguilar, R., Benhamed, N., & Shuler, F. D. (2017) · Marshall Journal of Medicine · doi:10.18590/mjm.2017.vol3.iss3.12
Johnson, K. M. (2017) · Journal of General Internal Medicine · doi:10.1007/s11606-017-4132-9
Implementing Pharmacist-Led Osteoporosis Testing and Education in Community Pharmacies
Chimezie, C. F., Williams, N., & Kinnard, H. (2014)
IMPACT OF NUTRACEUTICAL STIRRED YOGHURT ON OSTEOPOROSES USING THE OVARIECTOMIZED FEMALE WISTER RAT.
Ahmed, M., Aziz, M., SobhyH, M., et al. (2017) · International Journal of Advanced Research · doi:10.21474/ijar01/4836
Liu, S.-Y., & Sheng, Z. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01195
Acute Care and Geriatric Assessment
Gunathilake, R., & Nair, B. (2017) · Springer eBooks · doi:10.1007/978-981-10-3253-0_10
Cho, J., Lee, I., & Kang, H. (2017) · Exercise Science · doi:10.15857/ksep.2017.26.2.145
Metadata
- Authors
- Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R.
- Affiliations
- Helen Hayes Hospital (US)
- Brigham and Women's Hospital (US)
- New Mexico Clinical Research & Osteoporosis Center (US)
- Bone Health and Osteoporosis Foundation (US)
- Corresponding author
- Cosman, F.
- Venue
- Osteoporosis International
- Published
- 2014-08-15
- Volume
- 25
- Issue
- 10
- Pages
- 2359-2381
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- PMC
- PMC4176573
- OpenAlex
- W2171709369
- Semantic Scholar
- 91c0d02cdbd4c5dd69ed206e6a0b2b94c9aa0830
- Cited by
- 4,149
- References
- 101
- Citations by year
- 2026: 141 · 2025: 226 · 2024: 267 · 2023: 292 · 2022: 351 · 2021: 415 · 2020: 458 · 2019: 336 · 2018: 311 · 2017: 304 · 2016: 285 · 2015: 246 · 2014: 141
- FWCI
- 242.08
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-05-19)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Osteoporosis International (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Surgery › Hip and Femur Fractures
- Keywords
- osteoporosis, osteoporosis prevention, osteoporosis treatment, bone health, osteoporosis drugs
- MeSH terms
- Aged, Calcium, Dietary, Diet, Female, Humans, Male, Middle Aged, Osteoporosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.